Abstract
Background: Liver transplantation remains the best curation option in patients with Barcelona Clinic Liver Cancer (BCLC) stage A hepatocellular carcinoma (HCC) not amendable to surgical resection or ablation. During the mandatory 6-month waiting period, patients are often bridged to transplantation using liver-directed therapy. 90Yttrium (90Y) has been used across BCLC stages from A-C. Results from the LEGACY trial demonstrated high objective response rates (ORR) using 90Y in unresectable, solitary HCC. In this study, we investigated ORR and outcomes for BCLC-A HCC patients receiving 90Y as a bridge to liver transplantation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
